Spyre Therapeutics shares were up about 3% in Monday trading, a move that appears tied more to continued follow-through from April’s company-defining catalysts than to a brand-new headline. Investor attention has stayed on the April 13 topline Phase 2 SKYLINE-UC results for SPY001 in ulcerative colitis, followed quickly by an upsized equity raise that strengthened liquidity and extended operating runway.

On April 13, Spyre reported positive SPY001 Part A induction topline data from the SKYLINE trial in moderate-to-severe ulcerative colitis, including the study meeting its primary endpoint. Days later, the company priced an upsized common-stock offering at $62.00 per share and later announced the closing with full exercise of the underwriters’ option, lifting total gross proceeds to about $463.5 million.

A new Form 4 activity point is also in the mix: a May 1 filing disclosed CEO Cameron Turtle sold 15,000 shares in multiple open-market transactions under a pre-arranged Rule 10b5-1 plan adopted June 20, 2025. While insider sales can pressure sentiment, the planned nature of the transactions and the company’s recently improved cash position have helped keep dip-buying interest intact after recent volatility.